RxDoctor Payments Data

Jeetpaul Saran, MD

Internal Medicine · Tampa, FLNPI 1972701969

Payments from drug & device makers

$1,720in general payments, 2019–2025

Across 55 payments — averaging $31.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$367
  • Abbott$214
  • AbbVie$199
  • Genentech USA, Inc.$163
  • GSK$133
  • Novo Nordisk$130
  • plus $514 from 14 others

What the payments were for

  • Food & beverage$1,720100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,720 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$4,315,323
Medicare patients
301
Services billed
4,591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$40,585
MounjaroTirzepatide17$21,893
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,871
Repatha SureclickEvolocumab11$11,340
XareltoRivaroxaban16$10,363
MyrbetriqMirabegron22$5,094
Atorvastatin Calcium157$1,548
Rosuvastatin Calcium73$1,198
Levothyroxine Sodium109$1,145
Azelastine Hcl26$1,032
RivastigmineRivastigmine Tartrate13$1,007
Fluoxetine Hcl19$925
Gabapentin32$917
Pantoprazole Sodium56$847
Bupropion XlBupropion Hcl29$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$38$21,89317 claims
GSKTrelegy Ellipta$133$13,87119 claims
Johnson & JohnsonXarelto$30$10,36316 claims
Astellas Pharma US IncMyrbetriq$23$5,09422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →